Intelligence that compounds.
The longer we operate, the more we understand what moves, what works, and what the market actually needs. Aggregated, de-identified clinical data from across the network.
What the data covers
Clinical intelligence drawn from the intersection of every sponsor and every clinical endpoint in Australia.
Prescribing Trends
Aggregated prescribing patterns across conditions, dose forms, and cannabinoid profiles. See what the market is moving toward.
Outcome Signals
De-identified outcome data from the SureCan network. Understand what products are producing results for specific patient profiles.
Category Intelligence
Market share by category, formulation trends, pricing movements, and new product adoption rates across the Australian market.
Stock & Supply Patterns
Historical availability data, supply chain reliability metrics, and seasonal demand patterns to support forward planning.
Pharmacy Benchmarking
Anonymous benchmarking data so pharmacies can understand how their dispensing patterns compare to the broader network.
Compliance Intelligence
TGA regulatory updates, scheduling changes, and compliance requirement tracking relevant to your product portfolio.
Data principles
De-identified by default
All clinical data is aggregated and de-identified. Individual patient, prescriber, and pharmacy data is never exposed.
Sponsor-neutral analysis
Data is presented without commercial bias. No sponsor can pay for preferential positioning in clinical intelligence outputs.
Network-owned intelligence
The intelligence belongs to the network, not to any single brand. Every participant benefits from the collective data.